Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
- PMID: 9557630
- PMCID: PMC109570
- DOI: 10.1128/JVI.72.5.3520-3523.1998
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
Abstract
Sequences of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) domain were determined by direct sequencing of HIV-1 RNA in successive plasma samples from eight seroconverting patients infected with virus bearing the T215Y/F amino acid substitution associated with zidovudine (ZDV) resistance. At baseline, additional mutations associated with ZDV resistance were detected. Three patients had the M41L amino acid change, which persisted. Two patients had both the D67N and the K70R amino acid substitutions; reversion to the wild type was seen at both positions in one of these patients and at codon 70 in the other one. Reversion to the wild type at codon 215 was observed in only one of eight patients. Unusual amino acids, such as aspartic acid (D) and cysteine (C), appeared at position 215 in four patients during follow-up. These variants isolated by coculturing were sensitive to ZDV. Overgrowth of these variants suggests that they have better fitness than the original T215Y variant. Intraindividual nucleoside substitutions over time were 10 times more frequent in codons associated with ZDV resistance (41, 67, 70, 215, and 219) than in other codons of the RT domain. The predominance of nonsynonymous substitutions observed over time suggests that most changes reflect adaptation of the RT function. The variance in sequence evolution observed among patients, in particular at codon 215, supports a role for chance in the evolution of the RT domain.
Figures

Similar articles
-
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.J Virol. 2004 Jul;78(14):7545-52. doi: 10.1128/JVI.78.14.7545-7552.2004. J Virol. 2004. PMID: 15220429 Free PMC article.
-
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.J Virol. 2006 Jul;80(14):7020-7. doi: 10.1128/JVI.02747-05. J Virol. 2006. PMID: 16809307 Free PMC article.
-
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.J Virol. 2004 Sep;78(18):9987-97. doi: 10.1128/JVI.78.18.9987-9997.2004. J Virol. 2004. PMID: 15331732 Free PMC article.
-
The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.J Hum Virol. 1999 Sep-Oct;2(5):290-5. J Hum Virol. 1999. PMID: 10551735
-
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Antivir Ther. 2001;6 Suppl 3:25-44. Antivir Ther. 2001. PMID: 11678471 Review.
Cited by
-
Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.MedGenMed. 2006 Aug 7;8(3):32. MedGenMed. 2006. PMID: 17406166 Free PMC article. No abstract available.
-
Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds.PLoS Pathog. 2015 Mar 23;11(3):e1004722. doi: 10.1371/journal.ppat.1004722. eCollection 2015 Mar. PLoS Pathog. 2015. PMID: 25798934 Free PMC article. Clinical Trial.
-
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.J Virol. 2007 Mar;81(6):3037-41. doi: 10.1128/JVI.02712-06. Epub 2006 Dec 27. J Virol. 2007. PMID: 17192300 Free PMC article.
-
Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.Retrovirology. 2014 Nov 29;11:105. doi: 10.1186/s12977-014-0105-9. Retrovirology. 2014. PMID: 25575025 Free PMC article.
-
Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.PLoS One. 2018 Nov 8;13(11):e0206234. doi: 10.1371/journal.pone.0206234. eCollection 2018. PLoS One. 2018. PMID: 30408827 Free PMC article.
References
-
- Boucher C A, O’Sullivan E, Mulder J W, Ramautarsing C, Kellam P, Darby G, Lange J M, Goudsmit J, Larder B A. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992;165:105–110. - PubMed
-
- Brun-Vezinet F, Ingrand D, Desforges L, Gochi K, Ferchal F, Schmitt M P, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C, Fleury H. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods. 1992;37:177–188. - PubMed
-
- Coffin J M. HIV population dynamics in vivo: implication for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–489. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical